ABVX News Today: Stay Updated with the Latest Abivax S.A. News in Real Time
Find ABVX news now at Meyka AI. Stay informed with the latest Abivax S.A. stocks updates, including price news, market analysis, and expert insights.
GSK Plc Announces $10.6B Nuvalent Acquisition to Boost Lung Cancer Pipeline; Stock Falls 3.24%
GSK Plc moved decisively on June 9, 2026. The British drugmaker agreed to acquire US-listed cancer drug developer Nuvalent for $10.6 billion in an all-cash deal, valuing Nuvalent at approximately $124 per share, a 40% premium to its last closing price. Net of cash acquired, GSK’s actual upfront investment totals $9.4 billion. GSK Plc stock…
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns
French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…
Abivax Stock (EPA: ABVX) at 77.55 EUR, down 30.64% as Safety Signals Cloud Colitis Trial Results
Abivax Stock came under heavy pressure on June 2, 2026, after investors focused on safety concerns linked to its ulcerative colitis drug candidate, obefazimod. The stock fell 30.64% to 77.55 EUR even though the company reported stronger-than-expected Phase 3 trial results. The sharp selloff shows that safety signals can outweigh positive efficacy data in biotechnology…
ABIVAX SA Climbs 2.1% as Earnings Announcement Nears on May 25
ABVX.PA stock rises 2.1% to €105.1 ahead of May 25 earnings. Biotech firm faces profitability challenges with negative EPS of -4.83.
ABIVAX SA Stock Climbs 1.57% as Earnings Loom on May 25
ABVX.PA stock rises 1.57% to €97.10 ahead of May 25 earnings announcement. Biotech firm develops ABX464 for inflammatory and infectious diseases.
ABVX.PA ABIVAX SA (EURONEXT) -10.97% after hours 24 Mar 2026: catalysts ahead
ABVX.PA stock fell 10.97% after hours to EUR 97.40; analysis, Meyka AI grade and forecasts for investors.
Pre-market top loser: IPH.PA Innate Pharma €1.15 on 21 Mar 2026: earnings risk ahead
IPH.PA stock falls to €1.15 pre-market on 21 Mar 2026; analysis, grade, and Meyka AI forecast for near-term downside and catalysts
€107.40 ABVX.PA stock pre-market: earnings due Mar 23 may reset targets
Pre-market look at ABVX.PA stock ahead of Mar 23 earnings; price, forecasts, Meyka grade and analyst targets
ALMDP.PA Medesis Pharma EURONEXT €0.35 intraday Feb 19 2026: Oversold bounce
Intraday oversold bounce analysis of ALMDP.PA stock at €0.35 on EURONEXT on 19 Feb 2026 with Meyka AI insights